Search Results
You are looking at 1 - 2 of 2 items for
- Author: Andy G Lynch x
- Refine by access: Content accessible to me x
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Benjamin C Thomas in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Jonathan D Kay in
Google Scholar
PubMed
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Suraj Menon in
Google Scholar
PubMed
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Sarah L Vowler in
Google Scholar
PubMed
Search for other papers by Sarah N Dawson in
Google Scholar
PubMed
Search for other papers by Laura J Bucklow in
Google Scholar
PubMed
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley J Luxton in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Thomas Johnston in
Google Scholar
PubMed
Molecular and Computational Diagnostics Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Charlie E Massie in
Google Scholar
PubMed
Search for other papers by Michelle Pugh in
Google Scholar
PubMed
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Search for other papers by Peter Barker in
Google Scholar
PubMed
Search for other papers by Keith Burling in
Google Scholar
PubMed
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Search for other papers by Anne George in
Google Scholar
PubMed
Search for other papers by Johanna Burge in
Google Scholar
PubMed
Search for other papers by Marie Corcoran in
Google Scholar
PubMed
Search for other papers by Sara Stearn in
Google Scholar
PubMed
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Search for other papers by Naomi L Sharma in
Google Scholar
PubMed
University College Hospital at Westmoreland Street, London, UK
Search for other papers by Greg L Shaw in
Google Scholar
PubMed
Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Due to increased sensitivity, the expression of circulating nucleotides is rapidly gaining popularity in cancer diagnosis. Whole blood mRNA has been used in studies on a number of cancers, most notably two separate studies that used whole blood mRNA to define non-overlapping signatures of prostate cancer that has become castration independent. Prostate cancer is known to rely on androgens for initial growth, and there is increasing evidence on the importance of the androgen axis in advanced disease. Using whole blood mRNA samples from patients with prostate cancer, we have identified the four-gene panel of FAM129A, MME, KRT7 and SOD2 in circulating mRNA that are differentially expressed in a discovery cohort of metastatic samples. Validation of these genes at the mRNA and protein level was undertaken in additional cohorts defined by risk of relapse following surgery and hormone status. All the four genes were downregulated at the mRNA level in the circulation and in primary tissue, but this was not always reflected in tissue protein expression. MME demonstrated significant differences in the hormone cohorts, whereas FAM129A is downregulated at the mRNA level but is raised at the protein level in tumours. Using published ChIP-seq data, we have demonstrated that this may be due to AR binding at the FAM129A and MME loci in multiple cell lines. These data suggest that whole blood mRNA of androgen-regulated genes has the potential to be used for diagnosis and monitoring of prostate cancer.
Search for other papers by Charles E Massie in
Google Scholar
PubMed
Search for other papers by Inmaculada Spiteri in
Google Scholar
PubMed
Search for other papers by Helen Ross-Adams in
Google Scholar
PubMed
Search for other papers by Hayley Luxton in
Google Scholar
PubMed
Search for other papers by Jonathan Kay in
Google Scholar
PubMed
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Search for other papers by Mark J Dunning in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Search for other papers by Antonio Ramos-Montoya in
Google Scholar
PubMed
Search for other papers by Daniel S Brewer in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Colin S Cooper in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by Rosalind Eeles in
Google Scholar
PubMed
Search for other papers by UK Prostate ICGC Group in
Google Scholar
PubMed
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Search for other papers by Simon Tavaré in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Cancer Research UK Cambridge Institute, Division of Genetics and Epidemiology, Department of Biological Sciences and School of Medicine, Royal Marsden NHS Foundation Trust, Departments of Pathology, Urology, Surgical Oncology, University of Cambridge, Cambridge, CB2 0RE, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent founder mutations, consistent with non-genetic disease initiating events. Using methylation profiling in a series of multi-focal prostate tumours, we identify promoter methylation of the transcription factor HES5 as an early event in prostate tumourigenesis. We confirm that this epigenetic alteration occurs in 86–97% of cases in two independent prostate cancer cohorts (n=49 and n=39 tumour–normal pairs). Treatment of prostate cancer cells with the demethylating agent 5-aza-2′-deoxycytidine increased HES5 expression and downregulated its transcriptional target HES6, consistent with functional silencing of the HES5 gene in prostate cancer. Finally, we identify and test a transcriptional module involving the AR, ERG, HES1 and HES6 and propose a model for the impact of HES5 silencing on tumourigenesis as a starting point for future functional studies.